U.S. Food and Drug Administration said that it had approved Otsuka Pharmaceutical Co Ltd’s Abilify MyCite, the first drug with a digital ingestion tracking system to be approved in the United States.

The product, which uses digital tracking to record if the medication was taken, has been approved for the treatment of schizophrenia, treatment of psychological disorders.

The system sends a message from the pill’s sensor to a wearable patch, which then transmits the information to a mobile application, so that patients can track the ingestion of the medication on their smartphone. With permission, physicians can also track the patient's medication through a web-based portal.